<DOC>
	<DOCNO>NCT02565459</DOCNO>
	<brief_summary>The general aim present study test cell therapy third-party ex-vivo expand bone marrow-derived mesenchymal stromal cell ( MSCs ) strategy induce tolerance kidney transplant recipient decease donor . MSCs prepare accordingly establish protocol , start remnant bag filter end bone marrow infusion . From sample , MSCs expand good manufacturing practice ( GMP ) approve facility use present study patient undergo kidney transplantation . The propose study develop two phase : ) pilot explorative safety/biologic-mechanistic phase ( Phase A ) , ii ) pilot efficacy phase ( Phase B ) .</brief_summary>
	<brief_title>MSC Kidney Transplant Tolerance ( Phase A )</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>First single kidney transplant ; Capable understand purpose risk study ; Written inform consent . PRA &gt; 10 % ; Specific contraindication MSC infusion ; Any clinical relevant condition might affect study participation and/or study result ; Childbearing potential without effective contraception ; Pregnant woman nurse mother ; Unwillingness inability follow study protocol investigator 's opinion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Mesenchymal stromal cell</keyword>
	<keyword>kidney transplantation</keyword>
	<keyword>tolerance</keyword>
</DOC>